Search
Eucalyptol
go.drugbank.com/drugs/DB03852ApprovedInvestigationalNutraceuticalIt kills leukaemia cells in vitro. … Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant.
Mixtures: Demo Cineol InjCategories: Compounds used in a research, industrial, or household settingMethimazole
go.drugbank.com/drugs/DB00763ApprovedInvestigational[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive … Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA.
Isopropyl myristate
go.drugbank.com/drugs/DB13966ApprovedIsopropyl myristate is a moisturizer with polar characteristics used in cosmetics and topical medical preparations to ameliorate the skin absorption. … [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243] … Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists.
Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … In clinical trials, there were no differences in the safety profiles between younger and older (65 years of age and older) study participants.
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalnovel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalMutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
Salmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigational[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.
Prasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn Canada, a prescription is required to buy DHEA. … Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary.
Synonyms: 3β-hydroxyandrost-5-en-17-one, 3beta-hydroxyandrost-5-en-17-one